Phaseline

Targets › PPP2CB

PPP2CB (Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform): drug programs, companies and trials

1 program from 1 company in 4 trials: 4 Phase 1; Hematology, Oncology.

Catalytic subunit of protein phosphatase 2A (PP2A), a serine/threonine phosphatase involved in the regulation of a wide variety of enzymes, signal transduction pathways, and cellular events (Probable). PP2A can modulate the activity of phosphorylase B kinase, casein kinase 2, mitogen-stimulated S6 kinase, and MAP-2 kinase. (UniProt, P62714)

Open in Phaseline: the race on PPP2CB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Lixte Biotechnology HoldingsLB-100
Serine/threonine protein phosphatase 2A, catalytic subunit, alpha isoform inhibitor; Serine/threonine protein phosphatase 2A, catalytic subunit, beta isoform inhibitor; Serine/threonine-protein phosphatase 5 inhibitor
PPP2CA, PPP2CB, PPP5CPhase 1Myelodysplastic Syndromes; Advanced Soft-tissue Sarcoma; Extensive Stage Lung Small Cell Carcinoma; Metastatic Microsatellite-stable Colorectal Cancer–

Conditions

Myelodysplastic Syndromes (1) Advanced Soft-tissue Sarcoma (1) Extensive Stage Lung Small Cell Carcinoma (1) Metastatic Microsatellite-stable Colorectal Cancer (1)

Modalities

small molecule (1)

Companies

Lixte Biotechnology Holdings (1)

Related targets

PPP2CA (1) PPP5C (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.